Share Price | Bausch + Lomb Corp. Stock Analysis & Recommendation

Q: How big is Bausch + Lomb Corp.?

Market Cap: As of Jun 18, Bausch + Lomb Corp. has a market capitalization of 4,092.33 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Bausch + Lomb Corp. reported net sales of 4,829.00 million and a net profit of -353.00 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,473.00 million and total assets of 13,469.00 million.

Q: What does Bausch + Lomb Corp. do?

Overview:Bausch + Lomb Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.Financial Snapshot:Most recent Net Sales: 1,137 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -211 Million (Quarterly Results - Mar 2025) Market cap: USD 4,092.33 Million (Small Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.73 Return on Equity: -3.98% Price to Book: 0.64 Contact Details:Registrar Address: Not available.

Q: Is Bausch + Lomb Corp. overvalued or undervalued?

As of 3 May 2023, the valuation grade for Bausch + Lomb Corp. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued, given its Price to Book Value of 0.65 and an EV to EBITDA ratio of 14.88, which suggests that investors are paying a premium despite the company's current losses. Additionally, the ROCE stands at a mere 1.42%, further highlighting the challenges the company faces in generating returns.In comparison to its peers, Bausch + Lomb's valuation metrics are concerning; for instance, Penumbra, Inc. has a significantly higher P/E ratio of 75.41, while QIAGEN NV, which is considered fairly valued, has a more reasonable EV to EBITDA of 15.05. The company's recent stock performance has also lagged behind the S&P 500, with a year-to-date return of -14.84% compared to the index's gain of 12.22%. Overall, these factors suggest that Bausch + Lomb is currently overvalued in the market.

Q: Is Bausch + Lomb Corp. technically bullish or bearish?

As of 3 October 2025, the technical trend for Bausch + Lomb Corp. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supporting the positive shift, while the daily moving averages also indicate a bullish stance. However, the monthly MACD and Bollinger Bands remain bearish, suggesting mixed signals across different time frames. The stock has underperformed the S&P 500 across all multi-period returns, with a year-to-date decline of 17.55% compared to the S&P 500's gain of 14.18%. Overall, the current technical stance is mildly bullish, but caution is warranted due to the bearish monthly indicators.

Results Declared: Bausch + Lomb Corp. has declared results on 29 Apr 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

78.48 k

Shareholding (Mar 2026)

FII

3.62%

Held by 56 FIIs

DII

94.14%

Held by 8 DIIs

Promoter

1.38%

How big is Bausch + Lomb Corp.?

22-Jun-2025

As of Jun 18, Bausch + Lomb Corp. has a market capitalization of $4.09 billion, with recent net sales of $4.83 billion and a net profit of -$353 million.

View full answer

What does Bausch + Lomb Corp. do?

22-Jun-2025

Bausch + Lomb Corp. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1.137 billion and a net loss of $211 million as of March 2025. Key metrics include a market cap of $4.09 billion, a debt-to-equity ratio of 0.73, and a return on equity of -3.98%.

View full answer

Is Bausch + Lomb Corp. overvalued or undervalued?

20-Sep-2025

As of May 3, 2023, Bausch + Lomb Corp. is considered overvalued and risky due to its low Price to Book Value of 0.65, high EV to EBITDA ratio of 14.88, poor ROCE of 1.42%, and underperformance compared to the S&P 500, with a year-to-date return of -14.84%.

View full answer

Is Bausch + Lomb Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Bausch + Lomb Corp. shows a mildly bullish trend supported by the weekly MACD and daily moving averages, but caution is advised due to bearish monthly indicators and underperformance compared to the S&P 500.

View full answer

Compare Bausch + Lomb Corp. with Similar Stocks

Dentsply Sirona, Inc.Shockwave Medical, Inc.Bio-Rad Laboratories, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 2.16%

The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)

The company declared negative results in Mar'25 after positive results in Dec'24

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,843 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.73

Return on Equity

-3.88%

Price to Book

0.91

Revenue and Profits:

Net Sales:

1,244 Million

(Quarterly Results - Mar 2026)

Net Profit:

-70 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-5.88%

6 Months

3.03%

1 Year

46.79%

2 Years

10.8%

3 Years

-8.57%

4 Years

-20.0%

5 Years

0.0%

Bausch + Lomb Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

286.82%

EBIT Growth (5y)

128.19%

EBIT to Interest (avg)

-4.51

Debt to EBITDA (avg)

5.41

Net Debt to Equity (avg)

0.73

Sales to Capital Employed (avg)

0.41

Tax Ratio

8.95%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.62%

ROCE (avg)

2.16%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.91

EV to EBIT

56.20

EV to EBITDA

17.35

EV to Capital Employed

0.95

EV to Sales

2.07

PEG Ratio

Dividend Yield

ROCE (Latest)

1.68%

ROE (Latest)

-3.88%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 18 Schemes (0.86%)

Foreign Institutions

Held by 56 Foreign Institutions (3.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 9.41% vs 3.46% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 66.82% vs -29.45% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,244.00",
          "val2": "1,137.00",
          "chgp": "9.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "160.00",
          "val2": "45.00",
          "chgp": "255.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "100.00",
          "val2": "97.00",
          "chgp": "3.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.00",
          "val2": "-28.00",
          "chgp": "-17.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.00",
          "val2": "-211.00",
          "chgp": "66.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "47.40%",
          "val2": "-53.60%",
          "chgp": "10.10%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.47% vs 15.56% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.41% vs -22.98% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,101.00",
          "val2": "4,791.00",
          "chgp": "6.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "609.00",
          "val2": "642.00",
          "chgp": "-5.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "431.00",
          "val2": "412.00",
          "chgp": "4.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-102.00",
          "val2": "-61.00",
          "chgp": "-67.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-352.00",
          "val2": "-305.00",
          "chgp": "-15.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.90%",
          "val2": "43.00%",
          "chgp": "-0.61%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

1,244.00

1,137.00

9.41%

Operating Profit (PBDIT) excl Other Income

160.00

45.00

255.56%

Interest

100.00

97.00

3.09%

Exceptional Items

-33.00

-28.00

-17.86%

Consolidate Net Profit

-70.00

-211.00

66.82%

Operating Profit Margin (Excl OI)

47.40%

-53.60%

10.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 9.41% vs 3.46% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 66.82% vs -29.45% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

5,101.00

4,791.00

6.47%

Operating Profit (PBDIT) excl Other Income

609.00

642.00

-5.14%

Interest

431.00

412.00

4.61%

Exceptional Items

-102.00

-61.00

-67.21%

Consolidate Net Profit

-352.00

-305.00

-15.41%

Operating Profit Margin (Excl OI)

36.90%

43.00%

-0.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.47% vs 15.56% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.41% vs -22.98% in Dec 2024

All Annual Results

Company CV

About Bausch + Lomb Corp.

Bausch + Lomb Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available